BRCA-mutant pancreatic ductal adenocarcinoma
Cet article analyse les caractéristiques cliniques et génétiques des adénocarcinomes canalaires du pancréas avec mutation du gène BRCA1 ou BRCA2 puis passe en revue les stratégies thérapeutiques actuelles et celles en cours d'évaluation
Despite continued research, pancreatic ductal adenocarcinoma (PDAC) remains one of the main causes of cancer death. Interest is growing in the role of the tumour suppressors breast cancer 1 (BRCA1) and BRCA2—typically associated with breast and ovarian cancer—in the pathogenesis of PDAC. Indeed, both germline and sporadic mutations in BRCA1/2 have been found to play a role in the development of PDAC. However, data regarding BRCA1/2-mutant PDAC are lacking. In this review, we aim to outline the specific landscape of BRCA-mutant PDAC, focusing on heritability, clinical features, differences between BRCA1 and 2 mutations and between germline and sporadic alterations, as well as established therapeutic strategies and those that are still under evaluation.
British Journal of Cancer , résumé, 2021